The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...
Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase ...
Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...
There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University Hospital Essen on the PROMISE-PET registry 1, defining the potential prognostic ...
New research from NYU Langone Health detects microplastics in 9 out of 10 prostate cancer tumours, with levels 2.5× higher ...
In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...
Use of relugolix among prostate cancer patients is associated with QoL, high treatment adherence rates, and low rates of ...
A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...
The largest ever study of non-meat diets and cancer risk has found that vegetarian diets are associated with lower risks of several cancers—breast, prostate, kidney and pancreatic cancers, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results